SLAM-Dx SIGNED
Diagnostic drug response-profiling using SLAMseq
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SLAM-Dx project word cloud
Explore the words cloud of the SLAM-Dx project. It provides you a very rough idea of what is the project "SLAM-Dx" about.
Project "SLAM-Dx" data sheet
The following table provides information about the project.
| Coordinator |
FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH
Organization address contact info |
| Coordinator Country | Austria [AT] |
| Total cost | 150˙000 € |
| EC max contribution | 150˙000 € (100%) |
| Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
| Code Call | ERC-2019-PoC |
| Funding Scheme | ERC-POC-LS |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-10-01 to 2021-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | FORSCHUNGSINSTITUT FUR MOLEKULARE PATHOLOGIE GESELLSCHAFT MBH | AT (WIEN) | coordinator | 150˙000.00 |
Map
Project objective
One of the greatest challenges today is to select the right drug for the right patient at the right time. A lack of diagnostic tools for predicting therapy response currently hampers patient-tailored treatment decisions in the clinic with severe implications for economy and – most importantly – patient survival.
Profiling transcriptional responses to drug treatment is a key method for probing the activity of targeted therapeutics and guiding their use in the clinic. A major limitation of established gene expression profiling techniques (such as microarrays and RNA-seq) is their limited time resolution precluding the distinction of direct from secondary transcriptional responses to drug therapy. This hampers their utility for deciphering drug action and guiding patient-tailored treatment decisions.
To overcome this problem, as part of an ERC-StG project (Systematic in-vivo analysis of chromatin-associated targets in leukemia, 336860) I have co-developed thiol(SH)-linked alkylation for the metabolic sequencing of RNA (SLAMseq) as a rapid, robust and highly scalable method for the unbiased quantification of changes in mRNA production upon cell perturbations. Its unique features (low input cell numbers, short treatment-to-sample time, 1-day protocol library preparation in 96-well format) may qualify SLAMseq as the first method to probe the function, efficacy and selectivity of candidate therapeutics in primary (tumor) cells with unprecedented precision and on a large scale.
In this ERC-PoC project, I propose to establish technical and commercial proof-of-concept for SLAMseq’s application in preclinical and clinical drug development and optimization, and for patient-tailored treatment selection. Upon the successful proof-of-concept for SLAMseq’s application as diagnostic tool, SLAM-Dx has the potential to revolutionize translational research and personalised medicine in a variety of disease areas.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SLAM-DX" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SLAM-DX" are provided by the European Opendata Portal: CORDIS opendata.